858523-45-2

Usage

Chemical structure

A pyrazole derivative with a bromine substituent at the 4-position and a methyl group at the 3-position of the phenyl ring.

Application

Used in organic synthesis and medicinal chemistry as a building block for creating more complex molecules with potential biological activity.

Potential uses

Development of new pharmaceuticals, agrochemicals, or materials.

Specific properties

Vary depending on the intended application and the specific chemical reactions it undergoes.

Upstream product

• 102-52-3 malonaldehydebis(dimethylacetal) 
• 112626-91-2 (4-bromo-3-methylphenyl)hydrazine hydrochloride 

Downstream Products

• 858523-46-3 2-methyl-4-(pyrazol-1-yl)phenylboronic acid pinacol ester 
• 858523-47-4 2-methyl-4-(pyrazol-1-yl)phenylboronic acid 

Relevant academic research and scientific papers

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2n, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure (a) including pharmaceutically acceptable salts, esters, solvates, stereoisomers, and prodrugs thereof, wherein R1, R2, R3, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist and a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.